BACKGROUND AND OBJECTIVE: To report the design, methodology, implementation and initial results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) Registry, the first US patient registry to collect and report on practice patterns and outcomes associated with erythropoiesis-stimulating therapy (EST) for anaemia management in oncology patients. METHODS: DOSE is a prospective ongoing registry of oncology patients treated with epoetin-alpha or darbepoetin-alpha. Patients from either community or academic centres who meet prespecified entry criteria are eligible for inclusion in the registry. Data collected include patient demographic and clinical characteristics, EST administration, haematological parameters, patient-reported outcomes and medical resource utilization. Patients are followed from EST initiation through to the end of therapy or 16 weeks, whichever is earlier. RESULTS: Initial results from 45 sites for 861 patients (epoetin-alpha, n = 312; darbepoetin-alpha, n = 549) showed that baseline demographic and disease characteristics were similar between the two treatment groups. Administration of EST at both weekly and > or =2-weekly intervals was observed in both groups, with similar numbers of haemoglobin determinations. However, the mean number of office visits was higher in the darbepoetin-alpha group despite more frequent administration of therapy at > or =2-weekly intervals in this group. Mean treatment duration was approximately 8 weeks for both groups. Mean post-baseline haemoglobin levels of 11-12 g/dL were achieved and maintained at all timepoints assessed with epoetin-alpha but not with darbepoetin-alpha. Both groups had similar rates of packed red blood cell transfusions. CONCLUSIONS: The DOSE Registry is a valuable source of data relating to anaemia management, practice patterns and outcomes in oncology patients from the perspective of actual clinical practice. Results from this registry should provide patients, clinicians and healthcare decision makers with a better understanding of the relationship between EST dosage and outcomes in the clinical setting.
BACKGROUND AND OBJECTIVE: To report the design, methodology, implementation and initial results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) Registry, the first US patient registry to collect and report on practice patterns and outcomes associated with erythropoiesis-stimulating therapy (EST) for anaemia management in oncology patients. METHODS: DOSE is a prospective ongoing registry of oncology patients treated with epoetin-alpha or darbepoetin-alpha. Patients from either community or academic centres who meet prespecified entry criteria are eligible for inclusion in the registry. Data collected include patient demographic and clinical characteristics, EST administration, haematological parameters, patient-reported outcomes and medical resource utilization. Patients are followed from EST initiation through to the end of therapy or 16 weeks, whichever is earlier. RESULTS: Initial results from 45 sites for 861 patients (epoetin-alpha, n = 312; darbepoetin-alpha, n = 549) showed that baseline demographic and disease characteristics were similar between the two treatment groups. Administration of EST at both weekly and > or =2-weekly intervals was observed in both groups, with similar numbers of haemoglobin determinations. However, the mean number of office visits was higher in the darbepoetin-alpha group despite more frequent administration of therapy at > or =2-weekly intervals in this group. Mean treatment duration was approximately 8 weeks for both groups. Mean post-baseline haemoglobin levels of 11-12 g/dL were achieved and maintained at all timepoints assessed with epoetin-alpha but not with darbepoetin-alpha. Both groups had similar rates of packed red blood cell transfusions. CONCLUSIONS: The DOSE Registry is a valuable source of data relating to anaemia management, practice patterns and outcomes in oncology patients from the perspective of actual clinical practice. Results from this registry should provide patients, clinicians and healthcare decision makers with a better understanding of the relationship between EST dosage and outcomes in the clinical setting.
Authors: Arthur L Weaver; Richard L Lautzenheiser; Michael H Schiff; Allan Gibofsky; James L Perruquet; John Luetkemeyer; Harold E Paulus; H Amy Xia; Jonathan A Leff Journal: Curr Med Res Opin Date: 2006-01 Impact factor: 2.580
Authors: Michael N Neuss; Christopher E Desch; Kristen K McNiff; Peter D Eisenberg; Dean H Gesme; Joseph O Jacobson; Mohammad Jahanzeb; Jennifer J Padberg; John M Rainey; Jeff J Guo; Joseph V Simone Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: David H Henry; Lucio N Gordan; Veena Charu; Francois E Wilhelm; Denise Williams; John Xie; Richard C Woodman Journal: Curr Med Res Opin Date: 2006-07 Impact factor: 2.580
Authors: Jon D Herrington; Stephen L Davidson; Dianne K Tomita; Larry Green; Robert E Smith; Ralph V Boccia Journal: Am J Health Syst Pharm Date: 2005-01-01 Impact factor: 2.637
Authors: Paul J Hesketh; Francis Arena; Dhimant Patel; Matt Austin; Paul D'Avirro; Gregory Rossi; Alan Colowick; Lee Schwartzberg; Luigi F Bertoli; John T Cole; George Demetri; Emmanuel Dessypris; Tracy Dobbs; Peter Eisenberg; Roger Fleischman; James Hall; Phillip C Hoffman; Damian A Laber; John Leonard; Eric P Lester; Spence McCachren; Scott McMeekin; Luis Meza; David Scott Miller; Sucha Nand; Ira Oliff; Warren Paroly; Larry Pawl; Alejandra Perez; Harry Raftopoulos; James Rigas; Kendrith Rowland; Daniel C Scullin; Haluk Tezcan; John Waples; John Ward; Lorrin K Yee Journal: Cancer Date: 2004-02-15 Impact factor: 6.860
Authors: Chris L Pashos; Kay Larholt; Kimberly A Fraser; R Scott McKenzie; Mekré Senbetta; Catherine Tak Piech Journal: Support Care Cancer Date: 2011-02-27 Impact factor: 3.603